Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency


Abstract
A previously asymptomatic 30 year old man presented with rhabdomyolysis, muscle weakness, and acute encephalopathy after strenuous exertion in the cold without adequate food intake. Serum and muscle carnitine concentrations were decreased. Urinary excretion of carnitine and glyceric esters and biochemical examination of skeletal muscle and fibroblasts led to the diagnosis of medium chain acyl-CoA dehydrogenase (MCAD) deficiency. A point mutation at nucleotide position 985 of the coding region of the MCAD gene was found. The MCAD protein was synthesised in the patient's fibroblasts at a normal rate, but was unstable. In general, patients in whom the 985 point mutation has been established show much more severe clinical symptoms and other symptoms than those seen in this patient. The relation of the 985 point mutation and the residual MCAD activity to the symptoms is not as straightforward as previously thought.

Keywords: rhabdomyolysis; medium chain acyl-CoA dehydrogenase deficiency; encephalopathy

Rhabdomyolysis (acute muscle necrosis) can be due to various acquired or hereditary causes.1 2 The hereditary causes include specific defects of metabolism—for example, enzyme defects in glycogen catabolism and glycolysis.3 Of the disorders of muscle lipid metabolism, carnitine palmitoyltransferase deficiency is one of the most common metabolic causes of rhabdomyolysis.4 Recurrent attacks of rhabdomyolysis have been found in three patients reported to have myopathic carnitine deficiency.5 7 Recently a few other defects of fatty acid oxidation have been associated with rhabdomyolysis.8-10 Medium chain acyl-CoA dehydrogenase (MCAD) deficiency is thought to be the most common disorder of fatty acid oxidation.11 12 As an inborn error of metabolism it has been recognised with increasing frequency in children with a Reye-like syndrome. As a consequence of the disturbance in fatty acid oxidation, MCAD deficiency is associated with acute attacks of hypoketotic hypoglycaemia and C6-C10 dicarboxylic aciduria. The attacks are provoked by stress, fever, viral illness, and fasting. Some patients, earlier classified as having carnitine deficiency, later seemed to have MCAD deficiency.13 In urine a characteristic profile of C6-C10 acylcarnitines can usually be shown, as well as acylglycines (for example, suberylglycine). The presence of octanoylcarnitine in plasma may be a specific indication for MCAD deficiency.14

The age of initial presentation of MCAD deficiency varies widely. Most patients present acutely, usually between infancy and the second year of life. Duran et al described an asymptomatic adult man.15 Recent DNA studies have shown a high prevalence of a point mutation at nucleotide position 985 of the coding region of the MCAD gene in patients deficient in MCAD.16

Here we describe the first patient with an initial clinical presentation of rhabdomyolysis and acute encephalopathy in adult life, who was later proved to have MCAD deficiency, established both at the enzyme and DNA level.

Case history
A 30 year old man developed progressive muscle weakness in his arms and legs after a day of strenuous exercise in the cold without taking any food. He complained of headache and nausea, began vomiting, and produced dark brown coloured urine. At the end of the day he became lethargic, irritable, and agitated. He was admitted with lowered consciousness. He had had another episode of vomiting, headache, and motor restlessness one year before. This occurred during a long motorbike trip during which he did not eat. It was said that he sometimes had an acetone-like breath, especially when he had not eaten. The family history was non-contributory.

On admission the patient was delirious. Blood pressure, pulse rate, and temperature were normal. Due to generalised muscle weakness, he was unable to stand upright. Muscle stretch reflexes were normal and symmetric. His liver was not enlarged. There was no focal neurological deficit. On admission creatine kinase activity in serum was 4000 IU/l (normal range 15–91 IU/l) and myoglobin was 134 µg/l (normal < 85 µg/l). The calcium concentration of 2.20 mmol/l was low normal (normal range 2.20–2.60). Phosphate concentrations were increased to 1.70 mmol/l (normal range 0.76–1.24). Blood glucose was normal. Activity of transaminases in serum was raised, whereas γ-glutamyltransferase activity was normal. Potassium concentration was increased to 5.8 mmol/l (normal range...
Muscle (¿mol/g wet weight): during carnitine treatment in the patient and controls

Serum and muscle carnitine concentrations before and during carnitine treatment in the patient and controls

<table>
<thead>
<tr>
<th></th>
<th>Patient</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum (¿mol/l):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total carnitine</td>
<td>13–43</td>
<td>25–78</td>
</tr>
<tr>
<td>Non-esterified carnitine</td>
<td>6–38</td>
<td>13–41</td>
</tr>
<tr>
<td>Muscle (¿mol/g wet weight):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total carnitine</td>
<td>0.84</td>
<td>0.97</td>
</tr>
<tr>
<td>Non-esterified carnitine</td>
<td>0.73</td>
<td>0.61</td>
</tr>
</tbody>
</table>

MORPHOLOGICAL STUDIES
A biopsy from the vastus medialis muscle was taken one month after the rhabdomyolytic period. Only 20% of the fibres were type I (normal 35–50%). In semithin toluidine stained Epon sections there was an increased amount of lipid droplets between the myofibrils, mainly in type I fibres. Electron microscopy showed numerous lipid droplets as well as local glycogen accumulation. Morphometric studies showed that the volume density of lipid droplets (Vd): volume density of the myofibrils (Vmf) ratio was twice the control mean (Vd/Vmf patient 0.87 (SEM 0.15), controls 0.36 (SEM 0.07)).

BIOCHEMICAL ASPECTS
Concentrations of total and non-esterified carnitine in muscle tissue were about 25% of control values (table). The activities of carnitine palmitoyltransferase I and II, citrate synthase, creatine kinase, cytochrome c oxidase, palmitoyl-CoA synthetase, and succinate dehydrogenase were normal in skeletal muscle.

The oxidation rates of radiolabelled palmitate, octanoate, butyrate, and pyruvate by intact cultured fibroblasts were determined according to Veerkamp et al. The rate of octanoate was diminished to 5% of the control mean (0.11 ± 2.4 (SD 0.9)) nmol.h⁻¹. mg⁻¹ protein. MCAD deficiency was established in fibroblast homogenate (1.6 ± 15.6 (6.2) mU.U⁻¹ citrate synthase), using an electron transfer flavoprotein linked assay. The activities of short chain and long chain acyl-CoA dehydrogenases were normal. In a 800 g supernatant of a frozen skeletal muscle specimen, with phenazine methosulphate and dichlorophenolindophenol as electron acceptor, MCAD activity was not above the detection limit.

MOLECULAR BIOLOGICAL ASPECTS
Genomic DNA studies were performed on muscle tissue and skin fibroblasts. The DNA was extracted from cultured skin fibroblasts and skeletal muscle homogenate; 2 ¿g was used to amplify an 87 bp region using the polymerase chain reaction (PCR). The oligonucleotide primers used create a restriction site for NcoI in the mutant fragment. After an initial eight minute denaturation step at 94°C, the PCR reaction was repeated for 30 cycles (one minute denaturation at 94°C; two minutes annealing at 50°C; and three minutes extension at 72°C; the final extension was for eight minutes). The 87 bp PCR product was precipitated and resuspended in 20 ¿l of H2O. A 10 ¿l aliquot was digested with 5U of NcoI at 37°C for two hours. The original PCR fragment and the products of the restriction digest were treated by electrophoresis on a 3% agarose gel containing ethidium bromide.

Digestion with NcoI of the amplified DNA from the patient's fibroblasts and muscle showed only 61 and 26 bp fragments and no 87 bp fragment (fig 1, lanes 8 and 10). Therefore the patient was apparently homozygous for the 985 point mutation.
Rhabdomyolysis and acute encephalopathy in late onset medium-chain acyl-CoA dehydrogenase deficiency

The synthesis and stability of the MCAD protein was estimated in cultured skin fibroblasts. The normal medium for growing cells was Eagle's minimum essential medium (E-MEM) supplemented with 10% fetal calf serum (FCS) and antibiotics. For \(^{[35S]}\)methionine incorporation experiments medium was removed from confluent monolayers. Each dish (area 65 cm\(^2\)) was washed twice with phosphate buffered saline (PBS) and incubated at 37°C for two hours with 5 ml labelling medium (E-MEM without methionine but with 10% FCS). This medium was replaced by 5 ml of fresh labelling medium containing \(^{[35S]}\)methionine (100 \(\mu\)Ci). After incubation for one hour at 37°C the medium was removed. In some experiments the degradation of the synthesised protein was studied by incubating the cells for another six or 17 hours in normal medium with added unlabelled methionine. The cell layers were rinsed twice with PBS containing 2% unlabelled methionine and solubilised by the addition of 1 ml NETS medium (150 mM NaCl, 10 mM Tris-HCl, 0.5% Triton X-100, 0.25% sodium dodecylsulphate, and 2% unlabelled methionine, pH 7.4). The cell extract was centrifuged for one hour at 50 000 \(g\). The supernatant was mixed with antiserum raised against pig liver MCAD, \(^{29}\) and incubated overnight at 4°C. The antigen-antibody complex was precipitated by adding 100 \(\mu\)l of \textit{Staphylococcus aureus} cell suspension, followed by centrifugation (10 minutes at 1700 \(g\)). The pellet was washed four times with 2 ml of buffer containing 150 ml NaCl, 10 mM Tris-HCl, 1% Triton X-100, 1% deoxycholate, and 0.1% sodium dodecylsulphate, pH 7.2. The washed immunoprecipitate was solubilised by boiling (five minutes) in 50 \(\mu\)l of a denaturing buffer containing 8% mercaptoethanol and 0.003% bromophenol blue. After 10 minutes centrifugation at 6000 \(g\) the supernatant was subjected to SDS-PAGE electrophoresis according to Laemmli, \(^{27}\) with 12% gels. The gels were treated for fluorography with Autofluor (Amersham, Buckinghamshire, UK), dried, and fluorographed according to the supplier's instructions.

Figure 2 shows the representative MCAD synthesis pattern. The MCAD protein was synthesised by the patient's fibroblasts at a normal rate (lane 1). The rapid disappearance of the protein incorporated radiolabelled methionine suggests a reduced stability of the protein (lanes 2 and 3). This is likely due to the impaired ability of the mutant 44 kDa monomers to form a stable tetramer. \(^{28\text{-}30}\)

### Carnitine treatment

The patient was treated with 8 g DL-carnitine daily for nine months. During the first month of carnitine supplementation the patient noticed an improvement in his general condition. Total carnitine concentrations in serum increased to near normal values and became more constant. The concentration of carnitine in muscle after nine months of carnitine treatment had not increased (table), and lipid accumulation between the myofibrils had not disappeared. Supplementation was stopped as no objective improvement was seen.

Supplementation of 6 g/day riboflavin (the precursor of the flavin moiety of MCAD) had no beneficial effect.

### Physiological tests

These tests were performed after informed consent of the patient.

#### FASTING STUDIES

Prolonged fasting studies were performed before the diagnosis of MCAD deficiency was established. The blood concentrations of the most important metabolites were determined before and after the patient had been treated with carnitine for 40 days. Figure 3 shows the results. The concentration of non-esterified fatty acids and ketone bodies increased during fasting, whereas the ratio of ketone bodies:non-esterified fatty acids declined to 0.33 at 48 hours without carnitine supplementation. Glucose concentrations remained above 4.2 mmol/l for 48 hours, but declined
at 55 hours to 3.0 mmol/l. A more pronounced ketogenic response to fasting was found during carnitine treatment, whereas the non-esterified fatty acid concentration remained normal. The ketone bodies:non-esterified fatty acids ratio was 0.68 after a 48 hour fast. Glucose concentrations were maintained at 4.4 mmol/l. Apparently, the low carnitine concentrations had some pathophysiological consequences besides the MCAD deficiency.

EXERCISE TESTS
The patient participated in two prolonged exercise tests (again before the diagnosis was made), one before and one during carnitine treatment. The patient became confused and experienced myalgia and nausea at the end of the exercise test without carnitine. The normal glucose concentration could no longer be maintained and lactate and ammonia concentrations showed a pronounced rise. During carnitine treatment he performed the prolonged exercise test with only slight myalgia and felt well after finishing. The glucose, lactate, and ammonia concentrations did not become abnormal on this occasion.

Discussion
Since 1982 MCAD deficiency has been recognised in young children with episodic illness resembling Reye syndrome, provoked by viral illness, fever, and fasting. The first episode is often before the age of 2 years. The patients show a broad range of clinical presentation—namely, intolerance to fasting, episodic vomiting, lethargy, altered consciousness, and even coma. The outcome may be severe and fatal, although complete recovery has also been described. Dependent on the degree of involvement of the liver, heart, and skeletal muscle, the clinical features may range from recurrent episodes of hypoglycaemia to progressive muscle weakness and myalgia. Serum creatine kinase may be moderately increased. In many patients the muscular symptoms are not prominent, but some have symptoms of muscle weakness.

Techniques such as gas chromatography-mass spectrometry and fast atom bombardment mass spectrometry make it possible to establish this metabolic disorder easily. Recently the value of measuring octanoylcarnitine in plasma from patients suspected to have MCAD deficiency has been stressed. Deficiency of MCAD has been associated with a molecular lesion involving an A to G nucleotide replacement at position 985 of the MCAD coding sequence, resulting in replacement of lysine by glutamic acid. Although the prevalence of this mutation is high in patients deficient in MCAD, this approach is not yet appropriate to diagnose all patients with MCAD deficiency.

Until now only one asymptomatic adult with MCAD deficiency has been described, but his genotype was not established. We report the first patient with the MCAD point mutation at nucleotide position 985 whose clinical symptoms appeared at an adult age, whose medical history did not include muscle problems during childhood, and who did not have a positive family history. The clinical presentation of MCAD deficiency in this patient consisted of acute rhabdomyolysis and transient encephalopathy, provoked by prolonged exertion and fasting. Hitherto, rhabdomyolysis has not been associated with MCAD deficiency, although it has recently been described in several other defects of fatty acid oxidation. Fatty acids are important substrates for skeletal muscle, especially during prolonged exercise and fasting. The decreased oxidative capacity of muscle tissue can result in a moderate accumulation of lipid droplets.

The transient encephalopathy in the pre-
sent patient may be considered as a complication of rhabdomyolysis or a diminished supply of ketone bodies to the brain. The metabolism of the brain depends on glucose oxidation and, during fasting, on the oxidation of ketone bodies. Fatty acids are hardly metabolised by brain tissue. When the excess of medium chain fatty acids can no longer be metabolised by β-oxidation, as occurs in MCAD deficiency, ketogenesis becomes impaired and α-oxidation takes place. The impaired oxidation of octanoate may also have contributed to the development of encephalopathic symptoms. Octanoate disturbs the excretion of organic anionic compounds and mitochondrial functioning, especially in the choroid plexus. It also induces epileptic and encephalopathic symptoms. Carbohydrate supplementation can stimulate detoxification of octanoate by esterification, after which octanoylcarnitine is rapidly excreted.

"The main dietary advice for patients with disorders of fatty acid oxidation is to have an adequate carbohydrate intake at regular times." The supplementation of this patient's diet with carnitine has improved exercise tolerance and protected against the metabolic consequences of prolonged fasting.

It is remarkable that in our patient, with the aberrant clinical symptoms, the same point mutation and the same biochemical features have been found as in the far more severe cases of MCAD deficiency. Our patient shows the mutation in both alleles. The question arises as to which factor(s) determine this clinical heterogeneity. It has been shown that the 985 point mutation results in a diminished concentration of MCAD protein as a consequence of an enhanced degradation rate of the protein. Other point mutations, some of them being localised on exon 11 like the 985 mutation, have been found especially in compound heterozygotes. Possibly environmental factors or the relative activity of the other enzymes of β-oxidation play a part in determining the phenotype in patients deficient in MCAD. It is important to realise that in adults with unexplained rhabdomyolysis and acute encephalopathy a diagnosis of MCAD deficiency, or other disturbances in fatty acid oxidation, should be considered.

This investigation is part of the research programme Disorders of the Motor Unit and the Neuromuscular System of the University of Nijmegen. We are indebted to Professor J H Veerkamp (Department of Biochemistry, University of Nijmegen), Dr H J Ter Laak (Department of Chemical Pathology, University of Nijmegen), Professor A M Stachouderen (Department of Cell Biology, University of Nijmegen), Professor R C A Sengers, Professor J M Trijbels, Professor L A H Monnens, Dr J A M Bakkeren (Institute of Pediatrics, University of Nijmegen), and Dr S D Donato (National Institute of Neurology "C Besta", Milan) for investigations, discussion, and advice. R A C is grateful to Drs K N Prockop, LD, Engel WK, Shug AL, Nearl face muscle carnitine deficiency with full recovery after replacement therapy. Neurology 1985;35:1629-31.


Brakkeeje KP, Steegman DF, Joosten EMG. Increase in...


